首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1732163

全球生物可吸收支架市場規模（依材料類型、應用、最終用戶、地區、預測）- 2020 年

Bioabsorbable Stent Market Size By Material Type (Polymer-Based, Metal-Based), By Application (Coronary Artery Disease, Peripheral Artery Disease), By End-user (Hospitals, Cardiac Centers), By Geographic Scope And Forecast

出版日期: 2025年04月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

生物可吸收支架的市場規模及預測

2024 年全球生物可吸收支架市場規模為 4.4717 億美元，預計到 2032 年將達到 9.9397 億美元，2026 年至 2032 年的複合年成長率為 10.50%。

生物可吸收支架，也稱為生物可吸收血管支架 (BVS)，旨在為接受治療的血管提供支撐後隨著時間的推移被人體完全吸收。

這種創新設備的開發是為了克服永久性金屬支架的局限性，包括晚期支架血栓症和長期雙重抗血小板治療的需要。

此外，該技術旨在恢復血管的自然功能，同時減少與永久性植入相關的長期併發症。

生物可吸收支架市場動態

影響生物可吸收支架市場的關鍵市場動態是：

關鍵市場促進因素

心血管疾病（CVD）盛行率上升：全球心血管疾病負擔的增加是生物可吸收支架市場的主要驅動力。根據世界衛生組織（WHO）統計，心血管疾病每年導致約1,790萬人死亡，佔全球整體的32%。心臟疾病率的不斷上升推動了對生物可吸收支架的需求。生物可吸收支架具有與永久性植入相關的併發症較少的優勢，使其成為需要支架治療的患者的首選。

支架技術的進步：支架設計和材料的技術進步正在加速生物可吸收支架在冠狀動脈疾病治療中的應用。生物可吸收支架由生物分解性的聚合物製成，一旦達到保持動脈暢通的目的，就會自然分解。根據美國食品藥物管理局(FDA) 的研究，生物可吸收支架已顯示出減少支架血栓症等晚期問題的巨大潛力，從而改善患者預後並支持更廣泛的市場應用。

醫療保健支出的增加和可近性的提高：醫療保健基礎設施投資的增加和創新療法可近性的改善正在推動生物可吸收支架市場的發展。據世界銀行稱，全球醫療保健支出不斷增加，許多國家加大對先進心血管護理的投資。醫療保健支出的增加，加上人們試圖提供最尖端科技，推動了對生物可吸收支架作為冠狀動脈疾病有效治療方法的需求不斷成長。

主要挑戰

對臨床表現的擔憂：一些醫療保健提供者對生物可吸收支架的長期有效性和安全性提出了質疑。第一代支架曾出現過一些併發症，影響了市場信心。

監管障礙：新支架技術的核准必須遵守嚴格的監管要求。在任何新型支架上市前，監管機構都需要進行長期臨床試驗並提供安全資料。

製造成本高：事實證明，製造生物可吸收支架比傳統金屬支架更複雜、更昂貴。這些高昂的成本轉嫁給了醫療保健提供者和患者，限制了價格敏感市場的採用。

主要趨勢

個人化醫療方法：正在開發客製化支架設計以滿足個別患者的需求。利用先進的成像和 3D 列印技術，可以創建針對特定患者的設備。

專注於新材料：正在研究具有改進的機械性能和更可控的分解率的新型生物可吸收材料。正在研究結合聚合物和金屬優點的複合材料。

整合藥物釋放型功能：增強型藥物傳輸系統整合到可生物吸收支架中。這些進展旨在改善癒合效果並降低血管再阻塞的風險。

生物可吸收支架市場區域分析

北美：

根據 Verified Market Research 的調查，預計預測期內北美將主導生物可吸收支架市場。心血管疾病 (CVD) 仍然是北美最大的死亡原因，推動了對生物可吸收支架等先進治療方案的需求。根據美國心臟協會 (AHA) 的數據，到 2021 年，大約有 1.215 億美國成年人將患有某種形式的心血管疾病。這種高疾病負擔導致生物可吸收支架的採用率增加。與傳統金屬支架相比，生物可吸收支架可降低晚期支架血栓症的風險，且無需長期雙重抗血小板治療，提供更好的長期療效。

北美市場受益於鼓勵採用創新醫療技術的法律規範。美國食品藥物管理局（FDA）擴大核准治療冠狀動脈疾病的生物可吸收支架，以促進其在臨床實踐中的應用。近年來，FDA 透過其突破性設備計劃加快了生物可吸收支架的核准，從而加快了此類產品進入市場的速度並支持了該地區的發展。

此外，北美人口老化也對生物可吸收支架的需求成長產生了重大影響。根據美國人口普查局的報告，到2032年，嬰兒潮世代的年齡都將達到65歲或以上，這將導致與老齡化相關的心血管疾病的增加。由於老年人更有可能需要接受冠狀動脈疾病的支架手術，預計未來幾年對生物可吸收支架的需求將穩定成長，以減少長期併發症。

亞太地區：

預計亞太地區將在預測期內引領市場。在亞太地區，由於生活方式的改變和人口老化，心血管疾病（CVD）的盛行率不斷上升，這是生物可吸收支架市場的主要驅動力。根據世界衛生組織（WHO）統計，心血管疾病是造成中低收入國家，尤其是東南亞等地區過早死亡的75%以上的原因。心血管疾病負擔的持續加重推動了對先進療法的需求，例如生物可吸收支架，它可以透過減少長期併發症來幫助改善患者的治療效果。

亞太地區各國政府正在投資醫療保健基礎設施和改革，以改善獲得先進醫療技術的機會。例如，印度的國家衛生政策和中國的「健康中國2032」舉措都強調改善心血管護理，包括擴大尖端支架技術的可用性。這些政策鼓勵採用生物可吸收支架，作為加強全部區域心血管護理的更廣泛努力的一部分。

此外，由於提供高品質且價格合理的醫療服務，醫療旅遊業在亞太地區蓬勃發展，尤其是在印度、泰國和馬來西亞等國家。這一趨勢還包括對生物可吸收支架等先進心血管治療的需求不斷成長。據醫療旅遊協會稱，亞太地區是尋求心血管手術的醫療遊客的首選目的地。醫療旅遊業的成長促進了該地區生物可吸收支架市場的擴張。

生物可吸收支架市場細分分析

生物可吸收支架市場根據材料類型、應用、最終用戶和地區進行細分。

生物可吸收支架市場（依材料類型）

聚合物基
金屬底座

根據材料類型，生物可吸收支架市場分為聚合物基和金屬基。預計聚合物基支架將主導生物可吸收支架市場，因為它們具有優異的生物相容性和在體內緩慢的吸收性，從而減少了與永久性支架相關的長期併發症。聚合物支架具有靈活性和能夠藥物釋放型以防止血管再阻塞等優點，使其成為治療冠狀動脈疾病的理想選擇。聚合物材料的技術進步提高了機械強度並控制了分解，從而導致聚合物支架的採用率更高。

生物可吸收支架市場（依應用）

冠狀動脈疾病
周邊動脈疾病

根據應用，生物可吸收支架市場分為冠狀動脈疾病和周邊動脈疾病。冠狀動脈疾病 (CAD) 在世界範圍內十分常見，是導致死亡的主要原因之一，因此，冠狀動脈疾病領域預計將佔據生物可吸收支架市場的主導地位。生物可吸收支架在治療冠狀動脈疾病方面具有巨大優勢，它可為動脈提供臨時支撐，同時限制血管再阻塞和血栓症等長期併發症。藥物釋放型設計等生物可吸收支架的技術進步進一步提高了其治療 CAD 的有效性。周邊動脈疾病的治療也可以受益於生物可吸收支架，但由於患有 CAD 的患者群體龐大，因此該領域佔據市場主導地位。

生物可吸收支架市場（依最終用戶分類）

醫院
心臟中心
其他

根據最終用戶，生物可吸收支架市場分為醫院、心臟中心和其他。由於醫院進行的支架植入手術量大，醫院部門預計將主導生物可吸收支架市場。該醫院擁有先進的基礎設施和廣泛的專業服務，是需要冠狀動脈介入治療的患者的主要治療中心。此外，醫院可以使用更廣泛的生物可吸收支架技術，並且更有可能採用尖端的醫療創新。

生物可吸收支架市場（按地區）

北美洲
歐洲
亞太地區
世界其他地區

根據地區，生物可吸收支架市場分為北美、歐洲、亞太地區和世界其他地區。由於心血管疾病盛行率高、醫療基礎設施先進以及早期採用創新醫療技術等多種因素，北美預計將在生物可吸收支架市場佔據主導地位。該地區強而有力的法律規範在美國食品藥物管理局（FDA）的支持下，正在加速生物可吸收支架的核准和臨床使用。此外，北美受惠於對研發的大量投資，推動了生物可吸收支架技術的持續進步。雖然歐洲和亞太地區也是主要市場，但北美憑藉其強大的醫療保健體系和對微創手術的高需求在全球市場佔據主導地位。

主要企業

「生物可吸收支架市場」研究報告重點關注全球市場，提供了寶貴的見解。市場的主要企業包括雅培實驗室、波士頓科學公司、Biotronik SE &Co.KG、Elixir Medical Corporation、京都醫療規劃有限公司、Arterius Limited、Reva Medical, Inc.、Amaranth Medical, Inc.、Meril Life Sciences Pvt.Ltd. 和樂普醫療科技（北京）有限公司。

我們的市場分析還設有專門針對這些主要企業的部分，我們的分析師在其中提供所有主要企業的財務報表見解以及產品基準評效和 SWOT 分析。競爭格局部分還包括上述全球公司的關鍵發展策略、市場佔有率和市場排名分析。

生物可吸收支架市場的最新趨勢
2024 年 6 月，雅培獲得 FDA核准，推出採用改良的聚合物材料設計的下一代生物可吸收支架，以改善冠狀動脈疾病治療的患者預後。該支架具有更高的徑向強度和更可預測的分解特性，代表了生物可吸收支架技術的重大進步。
2024 年 4 月，Biotronik 在幾個歐洲國家推出了 Magmaris 可吸收鎂支架。該支架由鎂合金製成，可在被人體完全吸收的同時提供臨時血管支撐，從而減少傳統金屬支架帶來的長期併發症。

Rising Prevalence of Cardiovascular Diseases (CVDs): The growing global burden of cardiovascular illnesses is a key driver of the bioabsorbable stent market. According to the World Health Organization (WHO), CVDs kill around 17.9 million people each year, accounting for 32% of all global fatalities. The growing prevalence of cardiac disease is driving demand for bioabsorbable stents, which have the advantage of decreasing difficulties associated with permanent implants, making them the preferred choice for patients requiring stent-based treatments.

Advancements in Stent Technology: Technological advances in stent design and material have accelerated the use of bioabsorbable stents in the treatment of coronary artery disease. Bioabsorbable stents, created from biodegradable polymers, disintegrate naturally after serving their purpose of maintaining the artery. According to research from the United States Food and Drug Administration (FDA), bioabsorbable stents have shown substantial potential in lowering late-stage problems such as stent thrombosis, therefore improving patient outcomes and boosting wider market adoption.

Increasing Healthcare Expenditure and Accessibility: Growing investment in healthcare infrastructure and improved access to innovative medical treatments are propelling the bioabsorbable stent market. The World Bank said that worldwide healthcare spending has continuously increased, with many countries investing more in advanced cardiovascular treatment. This increase in healthcare spending, combined with attempts to provide access to cutting-edge technologies, is driving rising demand for bioabsorbable stents as an effective therapy for coronary artery disease.

Key Challenges

Clinical Performance Concerns: Questions about the long-term efficacy and safety of bioabsorbable stents are raised by some healthcare providers. Several first-generation devices have been associated with complications, which is affecting market confidence.

Regulatory Hurdles: Strict regulatory requirements are imposed for the approval of new stent technologies. Extended clinical trials and safety data are demanded by regulatory bodies before new devices are brought to market.

High Production Costs: The manufacturing of bioabsorbable stents is found to be more complex and expensive compared to traditional metallic stents. These higher costs are passed on to healthcare providers and patients, which is limiting adoption in price-sensitive markets.

Key Trends

Personalized Medicine Approach: Customized stent designs are developed to meet individual patient needs. Advanced imaging and 3D printing technologies are utilized to create patient-specific devices.

Focus on Novel Materials: Research is conducted on new bioabsorbable materials that offer improved mechanical properties and more controlled degradation rates. Composite materials that combine the benefits of both polymers and metals are explored.

Integration of Drug-Elution Capabilities: Enhanced drug-delivery systems are incorporated into bioabsorbable stents. These advancements are aimed at improving healing outcomes and reducing the risk of restenosis.

Bioabsorbable Stent Market Regional Analysis

The regional analysis of the bioabsorbable stent market:

North America:

According to Verified Market Research, North America is estimated to dominate the bioabsorbable stent market over the forecast period. Cardiovascular diseases (CVDs) remain a leading cause of death in North America, driving the demand for advanced treatment options like bioabsorbable stents. According to the American Heart Association (AHA), nearly 121.5 million American adults had some form of cardiovascular disease by 2021. This high disease burden has resulted in increased adoption of bioabsorbable stents, which offer better long-term outcomes compared to traditional metal stents by reducing the risk of late-stent thrombosis and eliminating the need for prolonged dual antiplatelet therapy.

The North American market benefits from a supportive regulatory framework that accelerates the adoption of innovative medical technologies. The U.S. Food and Drug Administration (FDA) has been increasingly approving bioabsorbable stents for coronary artery disease treatment, promoting their use in clinical settings. In recent years, the FDA has fast-tracked approvals for bioabsorbable stents under its Breakthrough Devices Program, enabling quicker market access and supporting growth in the region.

Furthermore, the aging population in North America significantly contributes to the rising demand for bioabsorbable stents. The U.S. Census Bureau reports that by 2032, all baby boomers will be over the age of 65, leading to an increase in age-related cardiovascular conditions. As older adults are more likely to require stent procedures due to coronary artery disease, the need for bioabsorbable stents, which reduce long-term complications, is expected to grow steadily in the coming years.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the market during the forecast period. The increasing prevalence of cardiovascular diseases (CVDs) in Asia-Pacific, due to lifestyle changes and aging populations, is a significant driver of the bioabsorbable stent market. According to the World Health Organization (WHO), CVDs account for over 75% of premature deaths in low- and middle-income countries, particularly in regions like Southeast Asia. This growing burden of CVDs is driving the demand for advanced treatments like bioabsorbable stents, which help improve patient outcomes by reducing long-term complications.

Governments in Asia-Pacific countries are investing in healthcare infrastructure and reforms to improve access to advanced medical technologies. For instance, India's National Health Policy and China's Healthy China 2032 initiative both emphasize improving cardiovascular care, including expanding the availability of cutting-edge stent technologies. These policies are encouraging the adoption of bioabsorbable stents as part of broader efforts to enhance cardiovascular treatment across the region.

Furthermore, the Asia-Pacific region, particularly countries like India, Thailand, and Malaysia, has seen rapid growth in medical tourism due to the availability of high-quality yet affordable healthcare. This trend includes a growing demand for advanced cardiovascular treatments such as bioabsorbable stents. According to the Medical Tourism Association, Asia-Pacific is one of the top destinations for medical tourists seeking cardiac procedures. This rise in medical tourism is contributing to the expansion of the bioabsorbable stent market in the region.

Bioabsorbable Stent Market: Segmentation Analysis

The Bioabsorbable Stent Market is segmented based on Material Type, Application, End-user, and Geography.

Bioabsorbable Stent Market, By Material Type

Polymer-Based
Metal-Based

Based on material type, the bioabsorbable stent market is segmented into Polymer-Based and Metal-Based stents. The polymer-based segment is estimated to dominate the bioabsorbable stent market due to its superior biocompatibility and gradual absorption in the body, reducing long-term complications associated with permanent stents. Polymer-based stents offer advantages such as flexibility and the ability to elute drugs to prevent restenosis, making them ideal for coronary artery disease treatment. Technological advancements in polymer materials have led to improved mechanical strength and controlled degradation, further driving the adoption of polymer-based stents.

Bioabsorbable Stent Market, By Application

Coronary Artery Disease
Peripheral Artery Disease

Based on application, the bioabsorbable stent market is segmented into Coronary Artery Disease and Peripheral Artery Disease. The coronary artery disease segment is estimated to dominate the bioabsorbable stent market due to the high prevalence of coronary artery disease (CAD) worldwide, which is one of the leading causes of death. Bioabsorbable stents offer significant advantages in the treatment of CAD by providing temporary support to arteries while reducing long-term complications such as restenosis and thrombosis. Technological advancements in bioabsorbable stents, such as drug-eluting designs, have further enhanced their effectiveness in treating CAD. While peripheral artery disease treatment also benefits from bioabsorbable stents, the large patient population suffering from CAD ensures this segment's dominance in the market.

Bioabsorbable Stent Market, By End-user

Hospitals
Cardiac Centers
Others

Based on End-user, the bioabsorbable stent market is segmented into Hospitals, Cardiac Centers, and Others. The hospital segment is expected to dominate the bioabsorbable stent market due to the high volume of stent implantation procedures performed in these settings. Hospitals, equipped with advanced infrastructure and a broad range of specialized services, are the primary point of care for patients requiring coronary interventions. Additionally, hospitals have access to a wider range of bioabsorbable stent technologies and are more likely to adopt cutting-edge medical innovations.

Bioabsorbable Stent Market, By Geography

North America
Europe
Asia Pacific
Rest of the World

Based on geography, the bioabsorbable stent market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region is estimated to dominate the bioabsorbable stent market due to several factors, including the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of innovative medical technologies. The region's strong regulatory framework, supported by the U.S. Food and Drug Administration (FDA), has accelerated the approval and clinical use of bioabsorbable stents. Additionally, North America benefits from significant investments in research and development, enabling continuous advancements in bioabsorbable stent technology. While Europe and Asia Pacific are also key markets, North America's robust healthcare system and high demand for minimally invasive procedures secure its leading position in the global market.

Key Players

The "Bioabsorbable Stent Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, Elixir Medical Corporation, Kyoto Medical Planning Co., Ltd., Arterius Limited, Reva Medical, Inc., Amaranth Medical, Inc., Meril Life Sciences Pvt. Ltd., and Lepu Medical Technology (Beijing) Co., Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Bioabsorbable Stent Market Recent Developments
In June 2024, Abbott received FDA approval for its next-generation bioabsorbable stent, designed with improved polymer materials for better patient outcomes in treating coronary artery disease. This stent offers enhanced radial strength and a more predictable degradation profile, making it a significant advancement in bioabsorbable stent technology.
In April 2024, Biotronik launched its Magmaris Resorbable Magnesium Scaffold in several European countries. The stent, made from magnesium alloy, provides temporary support to blood vessels while fully absorbed by the body, reducing long-term complications associated with traditional metal stents.

1 INTRODUCTION OF GLOBAL BIOABSORBABLE STENT MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
3.5 Market attractiveness

4 GLOBAL BIOABSORBABLE STENT MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BIOABSORBABLE STENT MARKET, BY MATERIAL TYPE

5.1 Overview
5.2 Polymer-Based
5.3 Metal-Based

6 GLOBAL BIOABSORBABLE STENT MARKET, BY APPLICATION

6.1 Overview
6.2 Coronary Artery Disease
6.3 Peripheral Artery Disease

7 GLOBAL BIOABSORBABLE STENT MARKET, BY END USER

7.1 Overview
7.2 Hospital
7.3 Cardiac Centers

8 GLOBAL BIOABSORBABLE STENT MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa

9 GLOBAL BIOABSORBABLE STENT MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 ACE Matrix

10 COMPANY PROFILES

10.1 Biotronik
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
10.2 Abbott Laboratories Inc.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
10.3 Boston Scientific Corporation
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
10.4 Terumo Corporation
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
10.5 Arterius Limited
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
10.6 Elixir Medical Corporation
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
10.7 Kyoto Medical Planning Co. Ltd
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
10.8 Amaranth Medical
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
10.9 Meril Life Sciences Pvt. Ltd
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
10.10 Reva Medical
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
10.11 Svelte Medical Systems
- 10.11.1 Overview
- 10.11.2 Financial Performance
- 10.11.3 Product Outlook
- 10.11.4 Key Developments
10.12 Lepu Medical Technology Co. LTD
- 10.12.1 Overview
- 10.12.2 Financial Performance
- 10.12.3 Product Outlook
- 10.12.4 Key Developments